Olga Danilchanka

Director/Board Member at

Therini Bio, Inc.

Consumer Services

Finance

Commercial Services

Profile

Olga Danilchanka is currently Director at Therini Bio, Inc. since 2021.
Dr. Danilchanka is also Partner at Merck Research Ventures since 2018, with the title of Partner starting in 2024.
Dr. Danilchanka earned a doctorate from The University of Alabama at Birmingham in 2010.

Olga Danilchanka active positions

Companies	Position	Start
Merck Research Ventures Merck Research Ventures Investment ManagersFinance Merck Research invests in companies located globally. The firm targets companies operating in the therapeutics sector. It participates in seed and early stage capital requirements with an investment size of up to USD 25 million. The firm acts as a lead and co-lead investor and takes a seat on the board of directors. It also makes follow-on investments and does not invest in medical devices, diagnostic platforms and digital health.	Private Equity Investor	01/05/2021
Therini Bio, Inc. Therini Bio, Inc. Miscellaneous Commercial ServicesCommercial Services Engages in research and development in halt chronic neuroinflammation and neuronal damage caused by vascular injury to treat severe neurological & retinal diseases	Director/Board Member	01/11/2021

All active positions of Olga Danilchanka

Training of Olga Danilchanka

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

See the detail of Olga Danilchanka's experience

Connections

1st degree connections

1st degree companies

Male

Female

Members of the board

Executives

See the personal network

Linked companies

Private companies	3
The University of Alabama at Birmingham The University of Alabama at Birmingham Other Consumer ServicesConsumer Services Functions as a College/University	Consumer Services
Merck Research Ventures Merck Research Ventures Investment ManagersFinance Merck Research invests in companies located globally. The firm targets companies operating in the therapeutics sector. It participates in seed and early stage capital requirements with an investment size of up to USD 25 million. The firm acts as a lead and co-lead investor and takes a seat on the board of directors. It also makes follow-on investments and does not invest in medical devices, diagnostic platforms and digital health.	Finance
Therini Bio, Inc. Therini Bio, Inc. Miscellaneous Commercial ServicesCommercial Services Engages in research and development in halt chronic neuroinflammation and neuronal damage caused by vascular injury to treat severe neurological & retinal diseases	Commercial Services